Nasus Pharma (NSRX) EPS (Weighted Average and Diluted) (2024)

Nasus Pharma (NSRX) reported EPS (Weighted Average and Diluted) of -$0.0 for Q4 2024.

Nasus Pharma (NSRX) EPS (Weighted Average and Diluted) (2024) Analysis & Trends

Nasus Pharma has reported EPS (Weighted Average and Diluted) for 1 years, with the latest figure at -$0.0 in Q4 2024.

For the quarter ending Q4 2024, EPS (Weighted Average and Diluted) changed N/A year-over-year to -$0.0; the trailing twelve-month figure through Dec 2024 stood at -$0.0 (changed N/A YoY), and the FY2025 full-year result was -$0.72, down 227.27% from the prior year.
EPS (Weighted Average and Diluted) for Q4 2024 stood at -$0.0.
The five-year high for EPS (Weighted Average and Diluted) was -$0.0 in Q4 2024, with the low at -$0.0 in Q4 2024.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EPS (Weighted Avg. Diluted) (Qtr)
1	Gsk	92,316,836.42 Bn	92,316,831.46 Bn	7.76 Bn	-
2	Eli Lilly	983.57 Bn	978.29 Bn	16.22 Bn	8.26
3	Johnson & Johnson	553.56 Bn	531.50 Bn	15.96 Bn	2.14
4	AbbVie	383.35 Bn	374.00 Bn	10.78 Bn	0.39
5	Merck	281.71 Bn	276.06 Bn	12.09 Bn	-1.72
6	Amgen	182.20 Bn	170.16 Bn	5.87 Bn	3.34
7	Gilead Sciences	153.71 Bn	145.98 Bn	5.52 Bn	1.61
8	Pfizer	143.75 Bn	130.98 Bn	-1.21 Bn	0.47
9	Bristol Myers Squibb	109.71 Bn	99.25 Bn	8.07 Bn	1.31
10	Nasus Pharma	24.83 Mn	20.55 Mn	-	-

Historic Data

Download Data

Date	Value
Dec 31, 2024	0.00